课题基金 / 基金详情

Development of tumor-targeted therapy using lentivirus-displayed antibody library

Development of tumor-targeted therapy using lentivirus-displayed antibody library
利用慢病毒展示抗体库开发肿瘤靶向治疗
批准号:
24650629
负责人:
NAKAMURA Takafumi
金额:
$2.5万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Challenging Exploratory Research
财政年份:
2012
资助国家:
日本
项目状态:
已结题
起止时间:
2012-04-01 至 2014-03-31

项目摘要

项目成果

NAKAMURA Takafumi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We previously showed that antibody-targeted cell fusion can be achieved by engineering a fusogenic viral membrane glycoprotein complex. Single-chain antibodies were displayed at the extracellular C terminus of the measles hemagglutinin (H) protein, and combinations of point mutations were introduced to ablate its ability to trigger fusion through the native viral receptors CD46 and SLAM. When coexpressed with the measles fusion (F) protein, the retargeted H proteins (Haals-scFvs) could mediate antibody-targeted cell fusion of receptor-negative or receptor-positive index cells with receptor-positive target cells. Now we have successfully pseudotyped lentiviral vectors with the glycoproteins Haals-scFv and F for targeted cell entry. Thus, the use of single chain antibodies for targeting potentially allows us to redirect the virus against any chosen cellular receptor. We also try to develop lentivirus-displayed scFvs library using the technology for identification of tumor-specific scFv.
期刊论文(28)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Naoyoshi Nitta, Nao Okada, Ikumi Goto, Motomu Nakatake, Masato Yamane, Hajime Kurosaki, Takafumi Nakamura, Takafumi Nakamura, Takafumi Nakamura, 中村貴史]
通讯作者: 中村貴史
ウイルスで新しいがん療法の開発をめざす
旨在利用病毒开发新的癌症疗法
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
臨床・創薬利用が見えてきたmiRcroRNA 「miRNA制御ウイルスによるがん細胞特異的治療法の開発」の項
开始用于临床和药物发现的 miRcroRNA “利用 miRNA 调节的病毒开发癌细胞特异性疗法”部分
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [Naoyoshi Nitta, Nao Okada, Ikumi Goto, Motomu Nakatake, Masato Yamane, Hajime Kurosaki, Takafumi Nakamura, Nakamura T, Nakamura T, 中村貴史, Nakamura T, Nakamura T, 中村貴史, 中村貴史]
通讯作者: 中村貴史
研究内容紹介
研究内容介绍
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
15
    Novel strategy of cancer virotherapy for radical cure of both primary and metastatic tumors
    • 批准号:
      19H03515
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.07万
    • 财政年份:
      2019
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    A novel oncolytic virotherapy for paclitaxel resistant ovarian cancer
    • 批准号:
      17K19597
    • 项目类别:
      Grant-in-Aid for Challenging Research (Exploratory)
    • 资助金额:
      $4.08万
    • 财政年份:
      2017
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    Tumor-targeted MAPK-dependent recombinant vaccinia virus for oncolytic virotherapy
    • 批准号:
      15H04310
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $10.82万
    • 财政年份:
      2015
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    Development of tumor-targeted therapy using measles virus-displayed antibody library
    • 批准号:
      22659227
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.06万
    • 财政年份:
      2010
    • 负责人:
      NAKAMURA Takafumi
    • 依托单位:
    国内基金
    海外基金
    第452位络氨酸磷酸化PI3Kp85抗体的制备方法和使用方法
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      迟寅秀
    • 依托单位:
    糖脂代谢重塑型金属多酚纳米药物促进CD8+ T细胞活化浸润增效PD-1抗体治疗三阴性乳腺癌的研究
    • 批准号:
      2026JJ50635
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2026
    • 负责人:
      刘芙蓉
    • 依托单位:
    抗BNLF2b抗体联合circRNA构建鼻咽癌早期诊断模型及机制研究
    ZW25联合PD-1抑制剂及化疗在HER2阳性肠癌中的协同抗肿瘤作用与机制研究